Sanwei Kangqiu Granules Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions

Sanwei Kangqiu Granules Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a granulated active pharmaceutical ingredient intermediate supplied for further manufacture rather than as a ready-to-dispense veterinary medicinal product. The trade designation identifies a particle-engineered granule form, not a single molecular entity; the active substance is described by the manufacturer’s batch documentation and specification. Published data specific to this configuration are limited. Therefore, the processing expectations described here are derived from general granulated veterinary API behavior and from compendial requirements applicable to the intended dosage forms. The material is supplied as free-flowing granules with reduced dust compared with micronized powders. Downstream operations such as blending, compression, capsule filling, sterile filtration, lyophilization, or feed premix dilution remain mandatory. The manufacturer’s public documentation does not assign an internal model code beyond the Sanwei Kangqiu Granules trade name. Incoming-material qualification should include identity testing against the manufacturer’s reference lot, because granule particle-size distribution alone cannot distinguish the active substance from a similarly granulated excipient.

What specification envelope governs release for a granulated veterinary API used across oral and parenteral routes?

The release-control matrix for a granulated API intended for multiple dosage forms is broader than that of a single-route intermediate because the same lot may be split between oral powders, tablets, injectable solutions, and medicated feed premixes. Release testing should be aligned with VICH GL18 for residual solvents where the material will enter a veterinary medicinal product, and with VICH GL11 for impurities. The receiving facility should verify that supplier analytical methods are equivalent to compendial methods where the active substance is monographed. Table 1 summarizes representative acceptance targets for orientation; the manufacturer’s certificate of analysis and the receiving veterinary drug facility’s quality unit define final limits.

Direct compression and capsule filling impose mechanical constraints that differ substantially from injectable solution manufacture. A granulated intermediate with Hausner ratio between 1.10 and 1.25 is typically compatible with rotary tablet presses operating at turret speeds of 30–80 rpm, because feed-frame pressure fluctuations remain low enough to hold tablet weight variability below 2% in validated processes. On dosator-type capsule fillers, plug formation and retained mass depend on the angle of internal friction and bulk density; granulated feed with bulk density in the 0.45–0.65 g/cm³ range generally supports plug weights from 150 mg to 800 mg, although exact limits must be established with the target capsule shell and fill volume. Excessive overgranulation can lower compressibility and increase capping tendency, so friability and hardness should be evaluated on research tablet batches before scale-up. A pre-drying step may be required if exposure to relative humidity above 60% increases moisture beyond the loss-on-drying specification in open manufacturing areas. This operational boundary applies to hygroscopic actives and should be confirmed by sorption isotherm data. Over-lubrication with magnesium stearate above 1.0% or extended blending beyond 5 min can reduce tablet tensile strength by surface coating the granules; this incompatibility is a formulation risk, not a property unique to the API.

In multi-component premixes and medicated granules, the granule particle size envelope should be matched to the carrier particle size to reduce segregation. Static sampling of finished premix should meet a coefficient of variation of ≤5% under the facility’s validated sampling plan. This target is an operational expectation, not a product-specific guarantee. If the API granules are too large relative to the carrier, jig-sifting during transport can separate the active. A particle-size ratio near 1:1 or an electrostatic charge match is preferred. Granulation lowers dust generation in high-shear mixing, but it does not remove the need for containment when the active substance is assigned to a high occupational exposure band. Wet granulation with aqueous or hydroalcoholic binders can introduce hydrolytic degradation if residual moisture is not controlled below the shelf-life specification.

When parenteral solutions and terminally sterilized formulations define the quality boundary

Injectable dosage forms derived from this material require a different control hierarchy because downstream sterile filtration cannot be assumed to remove pyrogen burdens contributed by the API. Bacterial endotoxin is not reliably removed by 0.2 µm sterilizing-grade filters; therefore the API lot entering solution preparation must carry a bioburden and endotoxin profile compatible with the maximum permitted dose. USP <85> and Ph. Eur. 2.6.14 provide the test framework, and a limit of 0.5 EU/mg is a common default when the active dose is below the parenteral threshold for pyrogen action. Where the product is intended for intramammary or intrauterine infusion, the same pyrogen logic applies because systemic absorption can occur. Subvisible particulate matter in the finished injectable solution is controlled by USP <788> light obscuration. For small-volume parenterals, the acceptance limit is 6000 particles per container at ≥10 µm and 600 particles per container at ≥25 µm; for large-volume parenterals, the corresponding limits are 25 particles per millilitre at ≥10 µm and 3 particles per millilitre at ≥25 µm. Although these are finished-product tests, an API with low dust and low insoluble particulate burden shortens filtration and reduces the likelihood of upstream particle loading.

The final injectable product must be sterile according to USP <71>, but the granule itself is not a sterile API. If terminal sterilization is intended, the formulation must withstand the heat exposure; if aseptic filtration is intended, the pre-filtration bioburden should be controlled to ≤10 CFU/100 mL as a commonly used prefilter bioburden action limit, although this limit must be validated for the specific line. Full dissolution and filtration compatibility studies, including filter extractables and leachables if product contact is extended, are required before aseptic filling.

In feed premix and oral powder applications, the granulated form differs from crystalline or micronized API primarily by its dust profile, bulk handling, and blending uniformity. A granulated intermediate reduces airborne dust during weighing, sifting, and ribbon blending relative to dry-milled powders. The lower surface area can also reduce moisture uptake, but this depends on the hygroscopicity of the active substance and the binder system used. Where the same granule is milled on-site to prepare oral solutions, the resulting particle size can be decoupled from the original granule distribution; the granule thereby functions as a stable intermediate for solution manufacture rather than as a rate-limiting dissolution substrate.

Differences from micronized, slugged, and roller-compacted veterinary API intermediates

The key distinction of the Sanwei Kangqiu Granules class is its intermediate particle architecture. Micronized powders with D90 below 50 µm are frequently cohesive and exhibit poor flow, whereas granules with D50 between 150 µm and 300 µm flow sufficiently for direct compression and low-dust premix operations. Roller-compacted granules can show high hardness and reduced dissolution if the compact pressure is too high; wet-granulated materials can retain moisture and require drying. Table 2 summarizes the comparative behavior.

Compared with spray-dried dispersions, which may be used for poorly soluble actives, the granule is not necessarily an amorphous solid-dispersed form. Unless otherwise stated, it maintains crystalline order and therefore offers lower solubility enhancement. If the active substance is thermolabile, granulation avoids the thermal stress associated with hot-melt extrusion or spray drying above 120 °C. For tablets and capsules, the granule must be characterized on production-scale equipment to determine whether additional intragranular disintegrant, lubricant, or filler is required. Direct compression is not a property of the API alone; a formulation containing 0.5–1.0% magnesium stearate and 2–5% croscarmellose sodium may be required to achieve acceptable disintegration. The granule particle size should be measured before and after blending to detect attrition. If the granules fragment excessively during transfer, the benefit of granulation is partially lost. In capsule filling, a powder-granule blend that retains 90% of its particle size distribution after 15 min of mixing is generally preferred, though the acceptance limit must be defined by process validation. For feed premixes, carryover and batch-to-batch homogeneity should be demonstrated under veterinary GMP and, where applicable, medicated feed regulations such as EU 2019/4 or FDA 21 CFR 558.